September 13, 2022 Thomas R. Kassberg Re: Amendment No. 2 to Offer Letter Dear Tom:Offer Letter • November 3rd, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
On behalf of Ultragenyx Pharmaceutical Inc. (the “Company”), I am pleased to present to you this Amendment No. 2 (this “Amendment”), which amends the Offer of Employment Letter Agreement with you dated October 31, 2011 and as amended by Amendment No. 1 dated August 8, 2014 (collectively, the “Offer Letter”) as follows:
AMENDMENT NO. 12 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 3rd, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 12 to the Collaboration and License Agreement, (“Amendment”) is made and entered into by and between Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin Co., Ltd.), a company organized and existing under the laws of Japan, with an address at 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“KKC”) and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA (“UGNX”). Each of KKC and UGNX shall be referred to herein as a “Party” and collectively, as the “Parties”.
AMENDMENT NO. 2 TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 3rd, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This Amendment No. 2 to Executive Employment Agreement (the “Amendment”), dated September 13, 2022 (the “Effective Date”), is between ULTRAGENYX PHARMACEUTICAL INC. (the “Company”) and EMIL D. KAKKIS, M.D., PH.D. (the “Executive”). Capitalized terms used but not defined herein have the meanings given to them in the Agreement (as defined below).
